Phenobarbital Antibody (402): sc-66076

Phenobarbital Antibody (402) is a mouse monoclonal IgG1 antibody that detects phenobarbital in non-species reactive samples through enzyme-linked immunosorbent assay (ELISA). Phenobarbital is a barbiturate that serves as a critical anticonvulsant, particularly recognized for its role as a first-line treatment for neonatal seizures. Anti-phenobarbital antibody (402) effectiveness in controlling seizures is comparable to that of phenytoin and carbamazepine, although phenobarbital is associated with more severe side effects, including dizziness, nystagmus, and ataxia. The importance of phenobarbital lies not only in therapeutic applications but also in metabolic pathways; phenobarbital is primarily metabolized in the liver through hydroxylation and glucuronidation, which are essential processes that influence pharmacokinetics and overall efficacy. Understanding the metabolism of phenobarbital is crucial, as this knowledge informs clinicians about potential drug interactions and the risk of toxicity, especially in patients with compromised liver function. With a molecular weight of 232.235 g/mol and a half-life ranging from 53 to 118 hours, phenobarbital′s pharmacological profile underscores the necessity for careful monitoring in therapeutic settings. Phenobarbital monoclonal antibody (402) is an invaluable tool for researchers and clinicians aiming to study the dynamics of this important anticonvulsant.